SUNY Poly Assistant Professor Dr. Amit Sangwan and colleagues recently published research titled "Feasibility Testing of the ...

Some patients with advanced heart failure can benefit from the support of a continuous-flow left ventricular assist device ...

Some patients with advanced heart failure can benefit from the support of a continuous-flow left ventricular assist device (CF-LVAD) to sustain heart function. However, despite improvements managing ...

Johnson & Johnson said Monday that a pivotal trial for the Impella ECP heart pump met its primary endpoint, positioning the company to seek Food and Drug Administration approval for the device.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

TCT 251: Practice Patterns and Percutaneous Coronary Intervention Outcomes in University Hospitals: A Comparison Between Sweden and the U.S. Receive the the latest news, research, and presentations ...

Impella ECP expands to 21Fr to provide circulatory support and left ventricular (LV) unloading for high-risk PCI. Impella ECP is an investigational device limited by federal law to investigational use ...

Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, the company noted. The pivotal investigational device exemption study, which enrolled 256 patients at 18 sites in the US ...

DANVERS, Mass., Oct. 28, 2024 /PRNewswire/ -- Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported ...

Recently, deep convolutional networks have been used to detect ventricular arrhythmias in IEGM recordings. However, due to their complex computations and model structures make them difficult to deploy ...